Cannabis Legalization is Leading to Increased Sales Expectations

Tuesday, June 12, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, June 12, 2018 /PRNewswire/ --

According to data provided

by research firm Cowen & Co., the U.S. legal cannabis industry is expected to reach USD 75 Billion in sales by 2030. The research explains that growing consumer support for legal cannabis, and increased access, is what
is driving meaningful change at the state level. Additionally, Cowen expects to see ballot initiatives to legalize cannabis for adult-use in both Michigan and Illinois in the upcoming midterm elections. Furthermore, expanded access in Maine, Massachusetts and New Jersey could prompt other states in the Northeast to make changes. Crop Infrastructure Corp. (OTC: CRXPF), Cannabis Sativa, Inc. (OTC: CBDS), iAnthus Capital Holdings Inc. (OTC: ITHUF), INSYS Therapeutics, Inc. (NASDAQ: INSY), Axim Biotechnologies, Inc. (OTC: AXIM)

According to a Bloomberg report, analyst Vivien Azer commented, "With the industries' diverging trajectories, weed may be poised to take the mantle as the larger industry. Cannabis is growing rapidly as more states legalize the plant. Nine states and Washington, D.C., now allow for recreational pot use. That means more than one in five American adults can smoke, vape, eat or drink it however they please. Cowen previously predicted that the market, assuming federal legalization, would reach $50 billion by 2026."

Crop Infrastructure Corp. (OTC: CRXPF) also listed on the Canadian Securities Exchange under the Ticker (CSE: CROP). Earlier last week the company announced breaking news that it, "has entered into a licensing agreement for four established cannabis brands that are currently being sold in Washington and will be available in California shortly:

  • Hempire;
  • Evolution Cannabis;
  • Tiffany CBD;
  • Trikom.

Crop will be sublicensing these established brands to its tenant growers in 

California and Washington.

Furthermore, Crop has acquired 10 additional brands for licensing to its tenant growers as follows:

  • Prohibition Greens;
  • Players Greens;
  • White Rhino Cannabis;
  • Illuminati Cannabis;
  • Diablo Herbs;
  • Gator Ganja;
  • Makavelli Cannabis;
  • Honey Badger Buds;
  • Choices Cannabis;
  • CHE Cannabis.

Crop Infrastructure director and chief executive officer Michael Yorke stated: "As the cannabis market grows and matures, consumers will choose brands that they trust to provide superior quality. Having unique and established brands that we will be able to license in Washington, California, other states and globally will be another benefit that Crop will be able to provide to its tenant growers."

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. PrestoDoctor Pennsylvania Expansion / Cannabis Sativa, Inc. announced on April 5th, 2018 that PrestoDoctor®, the leading online medical marijuana recommendation service, will be expanding to Pennsylvania on April 20th, 2018. More than 3,800 people have signed up in the medical marijuana patient registry's first week, signaling strong statewide interest in the program that will give those with one of 17 specific diagnoses access to cannabis beginning next year. "We are extremely excited to be expanding to Pennsylvania, and to help patients have easier access in obtaining a medical marijuana card," said PrestoDoctor® Co-Founder and CEO, Kyle Powers. "With so many people looking for an opioid alternative, and other natural options, it's important to provide an easy, honest, and affordable service," he added.

iAnthus Capital Holdings Inc. (OTCQB: ITHUF) owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. The company recently announced Q1 2018 results, highlighting the recorded $3.2 million of revenues in Q1 2018, compared to $0.3 million in Q1 2017. Additionally, in Massachusetts, the Company's Mayflower operation received its final certificate of registration from the Department of Public Health and began operations at its 36,000 square-foot Holliston cultivation and processing facility. At the close of Q1 2018, Mayflower was cultivating 2,670 plants, representing 15 different strains. In Florida, the Company signed leases for dispensary locations in West Palm Beach, Orlando, Tampa Bay, and Deerfield Beach. Furthermore, in New York, the Company acquired 8.5 acres of land for a planned 39,500 square-foot modular cultivation and processing facility; and signed a lease on the Company's flagship 2,000 square-foot dispensary in Brooklyn.

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced on May 8th, that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. "Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy," said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. "Considering the Lunatus footprint in the Middle East, we view this partnership as further validation of the important clinical role that SUBSYS® could play internationally for appropriately selected cancer patients with breakthrough cancer pain."

Axim Biotechnologies, Inc. (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the company has secured additional funding needed to further its clinical development program through S-3 stock purchases. "This financing highlights our investor's confidence in AXIM and our potential for success in cannabinoid-based pharmaceutical research," said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. "This deal will allow AXIM to move forward with a number of clinical projects including our bio-equivalent dronabinol chewing-gum based product and the MedChewRx™ program for treatment of pain and spasticity in Multiple Sclerosis patients."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For crop infrastructure corp. financial news dissemination and PR services, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

Media Contact: info@financialbuzz.com +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store